The XPNPEP1 antibody is a tool used to detect and study X-prolyl aminopeptidase 1 (XPNPEP1), a metallopeptidase involved in cleaving N-terminal amino acids adjacent to proline residues in peptides. XPNPEP1. also known as aminopeptidase P1. plays a role in regulating bioactive peptides, including bradykinin, collagen metabolites, and certain cytokines, influencing processes like inflammation, blood pressure regulation, and tissue remodeling. It is expressed in various tissues, notably the kidneys, liver, and intestines, and functions both intracellularly and on cell membranes.
Research on XPNPEP1 has linked it to diseases such as kidney disorders, hypertension, and inflammatory conditions. For instance, reduced XPNPEP1 activity is associated with impaired bradykinin metabolism, contributing to angioedema. Antibodies against XPNPEP1 are essential for investigating its expression, localization, and function in pathological contexts. They are employed in techniques like Western blotting, immunohistochemistry, and ELISA to quantify protein levels, assess tissue distribution, or explore molecular mechanisms in disease models.
Commercial XPNPEP1 antibodies are typically raised in rabbits or mice using recombinant protein fragments or synthetic peptides as immunogens. Validation includes specificity checks via knockout controls or siRNA knockdown. These reagents aid in advancing studies on peptidase biology, drug development targeting metabolic pathways, and understanding genetic variants linked to disease susceptibility.